Anna Patterson

Anna Patterson

Auto-generated profile, based on publicly available information

Anna Patterson

Department of Psychiatry, University of Illinois Chicago, Chicago, US

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 March 2025 in Science Translational Medicine
Verified
Journal Article
Closed access
OHOlivia R. Hoffman
Olivia R. Hoffman
JKJennifer L. Koehler
Jennifer L. Koehler
JEJose Ezekiel Clemente Espina
Jose Ezekiel Clemente Espina
APAnna M. Patterson
Anna M. Patterson
EGEmily S. Gohar
Emily S. Gohar
ARAvtar S. Roopra
Avtar S. Roopra
All current drug treatments for epilepsy, a neurological disorder affecting more than 50 million people, merely treat symptoms, and a third of patients with epilepsy do not respond to medication. There are no disease-modifying treatments that may be administered briefly to patients to enduringly eliminate spontaneous seizures and reverse cognitive deficits. Applying network approaches to whole tissue and single-nucleus transcriptomic data collected from mouse models of temporal lobe epilepsy and publicly available transcriptomic data from human temporal lobectomy samples, we confirmed a previously described pattern of rapid and transient induction of the Janus kinase/signal transducer and activator of transcription (JAK/STAT) pathway within days of epileptogenic insult. This was followed by a resurgent activation of the JAK/STAT pathway weeks to months later with the onset of spontaneous seizures. Targeting the first wave of JAK/STAT activation after epileptic insult did not prevent seizures. However, inhibition of the second wave with CP690550 (tofacitinib) over a 2-week period enduringly suppressed seizures, rescued deficits in spatial memory, and alleviated epilepsy-associated histopathological alterations. Seizure suppression lasted for at least 2 months after the final dose. These results indicate that reignition of inflammatory JAK/STAT3 signaling in chronic epilepsy opens a window for disease modification with the US Food and Drug Administration–approved, orally available drug CP690550.

1 June 2025 in Substance Use: Research and Treatment
Verified
Journal Article
Open access
APAnna Patterson
Anna Patterson
ZDZachary Davis
Zachary Davis
MSMackenzie Smith
Mackenzie Smith
NANihmotallahi Adebayo
Nihmotallahi Adebayo
MPMadelyn Perez
Madelyn Perez
SMSarah Messmer
Sarah Messmer
Background: Despite the continuing opioid overdose crisis, the majority of those diagnosed with opioid use disorder (OUD) are not engaged in treatment due to various barriers. Low-threshold buprenorphine programs are designed to reduce treatment barriers. Key tenets of these programs are a harm reduction approach, same-day entry, flexibility, and accessibility. The development of novel programs has expanded low-threshold treatment into mobile units, syringe service programs, and community centers. Objective: This scoping review aims to describe approaches taken by programs in non-clinical settings by identifying key components of delivery models, implementation barriers and facilitators, and outcomes. Given the diverse nature of the literature on these programs, a scoping review was selected to review outcomes and to identify gaps. Methods: A protocol following the PRISMA-ScR guidelines was developed to systematically search 5 databases: Medline, Embase, CINAHL, PsycInfo, and Web of Science. Articles published prior to January 31, 2024 that described buprenorphine programs operating outside traditional healthcare settings were included. Results: The search identified 18 784 articles, including 147 in full-text review, with 41 meeting eligibility criteria. Common program types encompassed syringe service, mobile, community center, and street medicine. All programs emphasized community partnerships as key implementation facilitators and noted funding is urgently needed. Conclusion: Low-threshold buprenorphine programs are an innovative way to deliver OUD treatment to people who otherwise may not have access to and/or engage in treatment. Future efforts should determine which outcomes are most important to people who use drugs, standardize outcome measurements, and implement programs tailored to help communities meet those outcomes.

20 December 2025 in Translational Psychiatry
Verified
Journal Article
Open access
PDF file
JBJordan C. Barone
Jordan C. Barone
RRRaffaele Romano
Raffaele Romano
ANAnisha Nagpal
Anisha Nagpal
ASAntonio Salerno
Antonio Salerno
APAnna Patterson
Anna Patterson
TETory A. Eisenlohr-Moul
Tory A. Eisenlohr-Moul
Menstrual cycle affective change (MCAC), including conditions like Premenstrual Dysphoric Disorder (PMDD), is triggered by ovarian hormone fluctuations, but its neurobiological mechanisms remain poorly understood. A leading hypothesis implicates abnormal GABA-A receptor (GABAAR) subunit regulation in altering sensitivity to neuroactive steroids, a theory difficult to test in humans. We examined peripheral mRNA expression of GABRD, GABRG2, and GABRA5 in a transdiagnostic sample of 112 participants (75 psychiatric outpatients with suicidality; 37 controls) to capture a dimensional range of MCAC severity. Participants provided daily affect ratings and five LH-timed blood samples using PAXgene tubes for RT-PCR analysis. Replicating preclinical findings, GABRG2 expression decreased during the midluteal phase. Critically, individual differences in both person-mean expression and perimenstrual change (AUCi) were correlated with cyclical symptom trajectories. Greater perimenstrual increases or higher average expression were associated with classic luteal-phase worsening of anxiety (GABRG2, GABRA5), irritability (GABRG2), and suicidal ideation (GABRG2, GABRA5, GABRD). However, relative to those with moderate or stable expression, perimenstrual decreases or lower average expression were also linked to cyclical worsening of anxiety and suicidal ideation that emerged around menses and persisted into the follicular phase. Overall, more stable subunit expression was associated with less cyclical symptom change. These findings could be consistent with a loss of homeostatic stability in GABAergic plasticity, rather than a simple unidirectional differences in levels or changes, as a potential correlate of MCAC. Peripheral GABAAR gene expression warrants further investigation, particularly in experimental studies, to determine whether there are causal associations between subunit gene expression and MCAC.

11 November 2026 in medRxiv
Verified
Preprint
Open access
PDF file
TETory A. Eisenlohr-Moul
Tory A. Eisenlohr-Moul
ARAshley Ross
Ashley Ross
JPJessica R. Peters
Jessica R. Peters
ANAnisha Nagpal
Anisha Nagpal
KSKatja Schmalenberger
Katja Schmalenberger
MMMichelle Martel
Michelle Martel
Objective: Patients often describe menstrual-cycle worsening of attention-deficit/hyperactivity disorder (ADHD). We prospectively evaluated sample- and person-level cycle effects on ADHD symptoms and their independence from cyclical negative affect and pain. Methods: In an intensive longitudinal cohort (2019-2024), 106 naturally cycling adults meeting DSM-5 ADHD criteria on integrated assessment rated daily inattention and hyperactivity-impulsivity (Barkley Adult ADHD Rating Scale-IV), negative affect, and pain (median, 41 days) and provided daily salivary estradiol and progesterone for ovulation coding and phase-aligned cycle time (PACTS). Generalized additive models estimated sample-level and person-specific cycle curves; robust cyclicity was tested against each participant’s own time-shuffle null. Lab cognitive testing at four counterbalanced phases provided post hoc validation. Results: Sample-average cycle effects were significant yet small (<1% of daily variance), but 54% of 87 participants tested individually were robustly cyclical in ADHD symptoms (95% CI, 44%-64%; inattention 43%, hyperactivity-impulsivity 26%), more often with informant-confirmed ADHD (69% vs 36%). Among them, the cycle explained median 52% and 51% of symptom variance, a mean swing of 2.6 and 2.1 DSM-5 criteria. Most remained cyclical after adjustment for affect (68%) or pain (81%). Worsening most often peaked at and after menses rather than premenstrually; no cycle met prospective criteria for premenstrual dysphoric disorder (PMDD). Hormones did not differ by cyclicity. Conclusions: About half of these adults with ADHD showed robust cyclical symptom change, mostly not reducible to cyclical affect or pain and usually outside the premenstrual window. Future work should test its stability and whether a DSM-5 cyclical specifier is warranted.